KR20140097118A - 항균 화합물 및 이의 사용 방법 - Google Patents

항균 화합물 및 이의 사용 방법 Download PDF

Info

Publication number
KR20140097118A
KR20140097118A KR1020147008210A KR20147008210A KR20140097118A KR 20140097118 A KR20140097118 A KR 20140097118A KR 1020147008210 A KR1020147008210 A KR 1020147008210A KR 20147008210 A KR20147008210 A KR 20147008210A KR 20140097118 A KR20140097118 A KR 20140097118A
Authority
KR
South Korea
Prior art keywords
alkyl
oxo
carboxylic acid
methyl
dihydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147008210A
Other languages
English (en)
Korean (ko)
Inventor
아서 브랜스톰
바라 프라사드 벤카타 나젠드라 조시울라
마이클 앤드류 아놀드
알렉세이 아이. 게라슈토
게리 카프
쟈시 왕
존 데이비드 베어드
구앙밍 첸
올리아 긴즈버그
제나 나라시만
스리니바사 페디
홍얀 치
션 웨슬리 스미스
매튜 지. 월
티안러 양
난징 쟝
시아오얀 쟝
Original Assignee
피티씨 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47756844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140097118(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피티씨 테라퓨틱스, 인크. filed Critical 피티씨 테라퓨틱스, 인크.
Publication of KR20140097118A publication Critical patent/KR20140097118A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147008210A 2011-08-29 2012-08-29 항균 화합물 및 이의 사용 방법 Withdrawn KR20140097118A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528599P 2011-08-29 2011-08-29
US61/528,599 2011-08-29
PCT/US2012/052922 WO2013033258A1 (en) 2011-08-29 2012-08-29 Antibacterial compounds and methods for use

Publications (1)

Publication Number Publication Date
KR20140097118A true KR20140097118A (ko) 2014-08-06

Family

ID=47756844

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147008210A Withdrawn KR20140097118A (ko) 2011-08-29 2012-08-29 항균 화합물 및 이의 사용 방법

Country Status (14)

Country Link
US (1) US9409905B2 (https=)
EP (1) EP2750504A4 (https=)
JP (1) JP2014525453A (https=)
KR (1) KR20140097118A (https=)
CN (1) CN103889224B (https=)
AU (1) AU2012301953C1 (https=)
BR (1) BR112014004515A2 (https=)
CA (1) CA2846663A1 (https=)
CL (1) CL2014000469A1 (https=)
HK (1) HK1199693A1 (https=)
IL (1) IL231060A (https=)
MX (1) MX2014002298A (https=)
WO (1) WO2013033258A1 (https=)
ZA (1) ZA201402248B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1199792A1 (en) * 2011-08-29 2015-07-24 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
WO2014139388A1 (en) * 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014157382A1 (ja) * 2013-03-29 2014-10-02 味の素株式会社 スフィンゴシンキナーゼ阻害剤
WO2016039939A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds
WO2016039937A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds
WO2016109706A1 (en) * 2014-12-31 2016-07-07 Ptc Therapeutics, Inc. Fused polycyclic 2-pyridinone antibacterial compounds
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
JP7153645B2 (ja) * 2017-06-08 2022-10-14 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
CN107325080B (zh) * 2017-08-30 2020-05-12 延边大学 含三嗪或氨基胍结构的咔唑类衍生物的制备方法及其抗菌应用
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
CN108659091B (zh) * 2018-05-24 2020-07-03 烟台大学 夫西地酸衍生物及其合成制备方法和应用
JP2021534246A (ja) * 2018-08-16 2021-12-09 レクレオ ファーマシューティカルス アイエヌシー 1,3,4,9−テトラヒドロ−2h−ピリド[3,4−b]インドール誘導体化合物及びその使用
CN109329290A (zh) * 2018-10-11 2019-02-15 四川省兰月科技有限公司 防治猕猴桃、柑橘黄化病的农药组合物
CN109485601B (zh) * 2018-12-23 2020-06-30 沧州普瑞东方科技有限公司 2,6-二卤吡啶-3-羧酸的合成方法
CN111521706A (zh) * 2020-05-11 2020-08-11 苏州必宜生物科技有限公司 一种快速检测血浆中头孢克肟浓度的方法
AU2022424463A1 (en) * 2021-12-28 2024-07-18 Adeka Corporation Aryl tetrahydropyridine derivative or salt thereof, pest control agent containing same, and method for use thereof
CN115960031B (zh) * 2023-01-06 2024-09-10 暨南大学 一种四氢异吲哚酮类化合物及其制备方法和应用
CN119569650A (zh) * 2024-12-05 2025-03-07 凯美克(上海)医药科技有限公司 一种7-溴-2-氯喹啉-4-醇的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3948903A (en) * 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US3954734A (en) 1974-01-21 1976-05-04 Parke, Davis & Company Novel antibacterial amide compounds and process means for producing the same
JPS5643288A (en) 1979-09-18 1981-04-21 Meiji Seika Kaisha Ltd Cephalosporin derivative and its preparation
JPS5651488A (en) 1979-10-02 1981-05-09 Meiji Seika Kaisha Ltd Penicillin derivative and its preparation
DE3338846A1 (de) * 1982-10-29 1984-05-03 Toyama Chemical Co. Ltd., Tokyo Neue 4-oxo-1,4-dihydronicotinsaeurederivate und salze derselben, verfahren zu ihrer herstellung und antibakterielle mittel mit einem gehalt derselben
EP0308020A3 (en) 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
GB8809481D0 (en) 1988-04-21 1988-05-25 Smith Kline French Lab Chemical compounds
IE911704A1 (en) * 1990-05-21 1991-12-04 Smith Kline French Lab Chemical compounds
DE19639817A1 (de) * 1996-09-27 1998-04-02 Hoechst Ag Verwendung von 1-Hydroxy-2-pyridonen zur Behandlung von Hautinfektionen
CN1231161A (zh) 1998-07-07 1999-10-13 邱泽国 全自动多功能超声波洗碗机
EP1343763A1 (en) 2000-11-20 2003-09-17 Bristol-Myers Squibb Company Pyrodone derivatives as ap2 inhibitors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ATE448784T1 (de) * 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
CN101531631B (zh) 2002-02-14 2011-09-28 法玛西雅公司 作为p38map激酶调节剂的取代吡啶酮类
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
CN101171247A (zh) * 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
WO2006117762A2 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Antimicrobial agents
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
HK1199792A1 (en) * 2011-08-29 2015-07-24 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
CA2846655A1 (en) * 2011-08-29 2013-03-07 Arthur Branstrom Antibacterial compounds and methods for use

Also Published As

Publication number Publication date
US9409905B2 (en) 2016-08-09
NZ623063A (en) 2016-04-29
CA2846663A1 (en) 2013-03-07
AU2012301953C1 (en) 2016-11-03
EP2750504A4 (en) 2015-03-11
CN103889224A (zh) 2014-06-25
ZA201402248B (en) 2016-06-29
CL2014000469A1 (es) 2014-11-14
EP2750504A1 (en) 2014-07-09
CN103889224B (zh) 2017-05-24
JP2014525453A (ja) 2014-09-29
WO2013033258A1 (en) 2013-03-07
AU2012301953A1 (en) 2014-03-13
BR112014004515A2 (pt) 2017-03-28
IL231060A0 (en) 2014-03-31
US20150038437A1 (en) 2015-02-05
IL231060A (en) 2017-01-31
MX2014002298A (es) 2014-07-22
HK1199693A1 (en) 2015-07-17
AU2012301953B2 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
AU2012301953B2 (en) Antibacterial compounds and methods for use
US9650395B2 (en) Antibacterial compounds and methods for use
TW202142542A (zh) 藉由軛合btk抑制劑與e3連接酶配位基降解布魯頓氏酪胺酸激酶(btk)及其使用方法
KR20140086958A (ko) 항균 화합물 및 이의 사용 방법
KR20150028999A (ko) 5-아자인다졸 화합물 및 이의 사용 방법
JP2014525453A5 (https=)
WO2013080222A1 (en) Substituted pyridine derivatives as fabi inhibitors
WO2016025933A2 (en) Substituted polycyclic antibacterial compounds
TW202342472A (zh) 治療神經疾病之方法(三)
KR20230022829A (ko) Rna 결합 단백질 또는 rna 변형 단백질을 표적으로 하는 화합물
TW202339733A (zh) 治療神經疾病之方法(一)
WO2014072930A2 (en) Fused pyridine derivatives as antibacterial agents
KR20240133695A (ko) Dyrk1a 억제제로서의 헤테로시클릭 화합물
WO2022115301A1 (en) Modified isoindolinones as glucosylceramide synthase inhibitors
WO2016025932A1 (en) Substituted polycyclic antibacterial compounds
WO2016039939A1 (en) Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds
NZ623063B2 (en) Antibacterial compounds and methods for use
NZ623056B2 (en) Antibacterial compounds and methods for use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140327

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid